Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00171
|
|||||
| Drug Name |
Loperamide
|
|||||
| Synonyms |
2-methoxyethyl1-methylethyl2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 4-(4-Chlorophenyl)-N,N-dimethyl-.alpha.,.alpha.-diphenyl-4-hydroxy-1-piperidinebutanamide; 4-(4-Chlorophenyl)-N,N-dimethyl-alpha,alpha-diphenyl-4-hydroxy-1-piperidinebutanamide; 4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide; Apo-Loperamide; Diamide (TN); Diarr-Eze; Dimor (TN); Imodium (TN); Imodium A-D Caplets; Ioperamide; Kaopectate II; Loperacap; Loperamida; Loperamida [INN-Spanish]; Loperamide (INN); Loperamide Monohydrochloride; Loperamide [INN:BAN]; Loperamidum; Loperamidum [INN-Latin]; Lopex (TN); Maalox Anti-Diarrheal; Nu-Loperamide; PMS-Loperamide; Pepto (TN); Pepto Diarrhea Control; R-18553; Rho-Loperamide
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Acute diarrhea [ICD11:ME05.1] | Approved | [1] | |||
| Therapeutic Class |
Antidiarrheals
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C29H33ClN2O2
|
|||||
| Canonical SMILES |
CN(C)C(=O)C(CCN1CCC(CC1)(C2=CC=C(C=C2)Cl)O)(C3=CC=CC=C3)C4=CC=CC=C4
|
|||||
| InChI |
InChI=1S/C29H33ClN2O2/c1-31(2)27(33)29(24-9-5-3-6-10-24,25-11-7-4-8-12-25)19-22-32-20-17-28(34,18-21-32)23-13-15-26(30)16-14-23/h3-16,34H,17-22H2,1-2H3
|
|||||
| InChIKey |
RDOIQAHITMMDAJ-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 53179-11-6
|
|||||
| Pharmaceutical Properties | Molecular Weight | 477 | Topological Polar Surface Area | 43.8 | ||
| Heavy Atom Count | 34 | Rotatable Bond Count | 7 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 3 | |||
| XLogP |
5
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10590039
,11111380
,11112740
,11113732
,11119963
,11120451
,11120939
,11121446
,11121926
,11147046
,11335390
,11360629
,11362515
,11363268
,11365077
,11365830
,11367639
,11368392
,11370301
,11370302
,11372088
,11373240
,11374823
,11375801
,11376554
,11461601
,11466172
,11467292
,11485552
,11485923
,11489554
,11490830
,11492957
,11494188
,14809921
,26751916
,26751917
,29223069
,46504591
,47216522
,47364910
,47515062
,47515063
,47588737
,47662002
,47662003
,5686070
,7979790
,8152483
,9291
|
|||||
| ChEBI ID |
ChEBI:6532
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| Drug-Transporter Activity Data | ||||||
| Drug-Transporter Activity Data | P-GP | Transporter Info | Km =13.8 microM | High five cells-MDR1 | [3] | |
| P-GP | Transporter Info | Km =11.4 microM | Spodoptera frugiperda (Sf9) cells-MDR1 | [2] | ||
| References | ||||||
| 1 | Loperamide was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab Dispos. 2008 Feb;36(2):268-75. | |||||
| 3 | Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.